Clearbridge Health also set to launch Precipio's Pathology Services and SmartPath™ Second Opinion Service
NEW HAVEN, CT / ACCESSWIRE / October 31, 2017 / Precipio, Inc. (NASDAQ: PRPO), announced today that Clearbridge Health, Pte. Ltd. (CBH), a Singapore-based healthcare company, intends to launch Precipio's RUO ICE COLD-PCR™ (ICP) Liquid Biopsy technology. CBH has placed an initial order of ICP kits to be delivered during Q4 of 2017 and Q1 2018. The Company also announced that CBH intends to launch Precipio's Pathology services, as well as its SmartPath™ Second Opinion service. SmartPath™ connects the patient and their treating physician with experts within Precipio's academic network to ensure accurate diagnoses. Precipio recently conducted comprehensive training at CBH headquarters in Singapore with the CBH sales team representatives covering Singapore, China, Hong Kong, India, Philippines, Malaysia and Indonesia.
"We are very excited about ICE COLD-PCR™ technology and Smartpath™," said Jeremy Yee, CEO of Clearbridge Health. "By working with Precipio, CBH can develop and offer an advanced, cost effective liquid biopsy solution throughout its network in Asia. This enables us to provide precision genomic profiling, which we believe supplies better information to the referring physician, leading to more effective treatment selection and ultimately results in better outcomes for patients with cancer, and other serious diseases."
CBH will begin the rollout of ICP and other services in Asia, where it has an established presence. Among its plans are to expand the installation of ICP in several Asian markets.
"Now that we have launched our first ICP kit, our goal is to rapidly increase the adoption of our ICE COLD-PCR™ (ICP) technology globally, and we believe that CBH is the ideal partner to help deliver ICP to the Asian markets," said Ilan Danieli, President and Chief Executive Officer of Precipio. "We are pleased to receive our first ICP kit order from Clearbridge Health; and to working with the CBH team to deliver improved, more accurate diagnoses to patients throughout Asia. We are also thrilled to commence offering our expert second opinion and pathology capabilities, as we drive value to clients receiving access to the highest quality healthcare services and gaining improved patient outcomes," Mr. Danieli added. "Clearbridge Health represents the first of many customers who see the value in Precipio's combined offering of technology (ICP) and services to meet their customer's clinical needs. This is the translation of the theoretical "synergies" that were envisioned in this merger, into practical, real customers and business growth."
About Clearbridge Health
CBH is a company with a focus on the delivery of precision medicine in Asia. CBH's business comprises laboratory testing services, medical clinics/centers and strategic equity participation in complementary precision medical technology companies. Through the delivery of precision medicine in Asia, it seeks to empower clinicians and healthcare professionals to make more reliable and accurate diagnosis, provide insights to disease management, and tailor personalized prevention and timely treatment programmed for patients. For more information, please visit us at www.clearbridgehealth.com.
About Precipio
Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise, and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, initially the Yale School of Medicine, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements," within the meaning of federal securities laws, including statements related to Precipio's merger with Transgenomic, consolidation of laboratory operations, reductions of accounts payable, plans and prospects and other statements containing the words "anticipate," "intend," "may," "plan," "predict," "will," "would," "could," "should," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the known risks, uncertainties and other factors described in the Company's definitive proxy statement filed on May 12, 2017, the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, the Company's prior filings and from time to time in the Company's subsequent filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events, and performance to differ materially from those referred to in such statements. All information in this press release is as of the date of the release and the Company does not undertake any duty to update this information, including any forward-looking statements unless required by law.
Contacts:
Precipio Investor Relations:
John Marco
Managing Director
Core IR
377 Oak Street
Garden City, NY 11530
516 222 2560
[email protected]
www.coreir.com
SOURCE: Precipio, Inc.